/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of.
Pfizer has enrolled the first subjects in a study exploring the co-administration of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 vaccine.
The trial will cover a cohort of 600 adults aged 65+, taken from last year’s COVID-19 Phase 3 vaccine trial.
Having received their second dose of the COVID-19 vaccine at least six months ago, participants will be randomized into groups to receive either a COVID-19 booster with 20vPnC; a placebo COVID-19 shot with 20vPnC; or a COVID-19 vaccine with placebo 20vPnC.
The primary objective of the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.
ABBVie announced today that the European Commission has approved VENCLYXTO ® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. 1 The approval is valid in all 27 member states of the EU, as well as Iceland Liechtenstein and Norway . “VENCLYXTO has proven incremental …
– ABBVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. 1 The approval is valid in all 27 member states of the EU, as well as Iceland Liechtenstein and Norway .
/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated.
Date Time
Share
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of Pfizer-BioNTech COVID-19 Vaccine
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines.